Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Research output: Contribution to journalArticle

Standard

Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. / Gissen, Paul; Preece, Mary; Willshaw, HA; McKiernan, Patrick.

In: Journal of Inherited Metabolic Disease, Vol. 26, No. 1, 01.01.2003, p. 13-6.

Research output: Contribution to journalArticle

Harvard

Gissen, P, Preece, M, Willshaw, HA & McKiernan, P 2003, 'Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.', Journal of Inherited Metabolic Disease, vol. 26, no. 1, pp. 13-6.

APA

Vancouver

Author

Gissen, Paul ; Preece, Mary ; Willshaw, HA ; McKiernan, Patrick. / Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. In: Journal of Inherited Metabolic Disease. 2003 ; Vol. 26, No. 1. pp. 13-6.

Bibtex

@article{79839baf96364e079b15787e1f800315,
title = "Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.",
abstract = "NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.",
author = "Paul Gissen and Mary Preece and HA Willshaw and Patrick McKiernan",
year = "2003",
month = jan,
day = "1",
language = "English",
volume = "26",
pages = "13--6",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

AU - Gissen, Paul

AU - Preece, Mary

AU - Willshaw, HA

AU - McKiernan, Patrick

PY - 2003/1/1

Y1 - 2003/1/1

N2 - NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.

AB - NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.

M3 - Article

C2 - 12872835

VL - 26

SP - 13

EP - 16

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 1

ER -